Pamela M Marcus1, Sheryl L Ogden2, Lisa H Gren3, Jeffery C Childs4, Shannon M Pretzel5, Lois E Lamerato6, Kayo Walsh7, Heather M Rozjabek8, Jerome Mabie9, Brett Thomas10, Tom Riley11. 1. National Cancer Institute, Division of Cancer Control and Population Sciences, 9609 Medical Center Dr, Room 4E-608, Bethesda, MD 20892-9763, USA. Electronic address: marcusp@mail.nih.gov. 2. Colorado Colorectal Screening Program, University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO 80045, USA. Electronic address: Sheryl.ogden@ucdenver.edu. 3. University of Utah, Department of Family and Preventive Medicine, 375 Chipeta Way, Salt Lake City, UT 84108, USA. Electronic address: Lisa.gren@hsc.utah.edu. 4. University of Utah, Division of Oncology, 2000 Circle of Hope, Room LL376, Salt Lake City, UT 84112, USA. Electronic address: jeff.childs@hsc.utah.edu. 5. University of Colorado Anschutz Medical Campus, 13001 E 17th Pl, Aurora, CO 80045, USA. Electronic address: Shannon.pretzel@ucdenver.edu. 6. Department of Public Health Sciences, Henry Ford Health System, 1 Ford Place, Detroit, MI 48202, USA. Electronic address: llamera1@hfhs.org. 7. Harvard Medical School, 180 Longwood Ave, Boston, MA 02115, USA. Electronic address: walsh@hcp.med.harvard.edu. 8. National Cancer Institute, Division of Cancer Control and Population Sciences, 9609 Medical Center Dr, Room 4E-608, Bethesda, MD 20892-9763, USA; Drexel University School of Public Health, 1505 Race St., Philadelphia, PA 19102, USA. Electronic address: heather.rozjabek@gmail.com. 9. Information Management Systems, 6110 Executive Blvd, Rockville, MD 20852, USA. Electronic address: mabiej@imsweb.com. 10. Information Management Systems, 6110 Executive Blvd, Rockville, MD 20852, USA. Electronic address: thomasb@imsweb.com. 11. Information Management Systems, 6110 Executive Blvd, Rockville, MD 20852, USA. Electronic address: rileyt@imsweb.com.
Abstract
OBJECTIVE: Identify predictors of non-compliance with first round screening exams in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. METHOD: The PLCO was conducted from 1993 to 2011 at 10 US institutions. A total of 154,897 healthy men and women ages 55-74 years were randomized. Intervention arm participants were invited to receive gender-appropriate screening exams for prostate, lung, colorectal and ovarian cancer. Using intervention-arm data (73,036 participants), non-compliance percentages for 13 covariates were calculated, as were unadjusted and adjusted odds ratios (ORs), and 95% confidence intervals. Covariates included demographic factors as well as factors specific to PLCO (e.g., method of consent, distance from screening center). RESULTS: The rate of non-compliance was 11% overall but varied by screening center. Significant associations were observed for most covariates but indicated modest increases or decreases in odds. An exception was the use of a two-step consent process (consented intervention arm participants for exams after randomization) relative to a one-step process (consented all participants prior to randomization) (OR: 2.2, 95% CI: 2.0-2.5). Non-compliance percentages increased with further distance from screening centers, but ORs were not significantly different from 1. CONCLUSIONS: Many factors modestly influenced compliance. Consent process was the strongest predictor of compliance. Published by Elsevier Inc.
RCT Entities:
OBJECTIVE: Identify predictors of non-compliance with first round screening exams in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. METHOD: The PLCO was conducted from 1993 to 2011 at 10 US institutions. A total of 154,897 healthy men and women ages 55-74 years were randomized. Intervention arm participants were invited to receive gender-appropriate screening exams for prostate, lung, colorectal and ovarian cancer. Using intervention-arm data (73,036 participants), non-compliance percentages for 13 covariates were calculated, as were unadjusted and adjusted odds ratios (ORs), and 95% confidence intervals. Covariates included demographic factors as well as factors specific to PLCO (e.g., method of consent, distance from screening center). RESULTS: The rate of non-compliance was 11% overall but varied by screening center. Significant associations were observed for most covariates but indicated modest increases or decreases in odds. An exception was the use of a two-step consent process (consented intervention arm participants for exams after randomization) relative to a one-step process (consented all participants prior to randomization) (OR: 2.2, 95% CI: 2.0-2.5). Non-compliance percentages increased with further distance from screening centers, but ORs were not significantly different from 1. CONCLUSIONS: Many factors modestly influenced compliance. Consent process was the strongest predictor of compliance. Published by Elsevier Inc.
Entities:
Keywords:
Adherence; Cancer; Compliance; Mass screening; Randomized controlled trial as subject
Authors: Martin M Oken; Willam G Hocking; Paul A Kvale; Gerald L Andriole; Saundra S Buys; Timothy R Church; E David Crawford; Mona N Fouad; Claudine Isaacs; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Lawrence R Ragard; Joshua M Rathmell; Thomas L Riley; Patrick Wright; Neil Caparaso; Ping Hu; Grant Izmirlian; Paul F Pinsky; Philip C Prorok; Barnett S Kramer; Anthony B Miller; John K Gohagan; Christine D Berg Journal: JAMA Date: 2011-10-26 Impact factor: 56.272
Authors: Stephanie R Land; Walter M Cronin; D Lawrence Wickerham; Joseph P Costantino; Nicholas J Christian; William M P Klein; Patricia A Ganz Journal: Cancer Prev Res (Phila) Date: 2011-08-23
Authors: Robert E Schoen; Paul F Pinsky; Joel L Weissfeld; Lance A Yokochi; Timothy Church; Adeyinka O Laiyemo; Robert Bresalier; Gerald L Andriole; Saundra S Buys; E David Crawford; Mona N Fouad; Claudine Isaacs; Christine C Johnson; Douglas J Reding; Barbara O'Brien; Danielle M Carrick; Patrick Wright; Thomas L Riley; Mark P Purdue; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; John K Gohagan; Philip C Prorok; Christine D Berg Journal: N Engl J Med Date: 2012-05-21 Impact factor: 91.245
Authors: P C Prorok; G L Andriole; R S Bresalier; S S Buys; D Chia; E D Crawford; R Fogel; E P Gelmann; F Gilbert; M A Hasson; R B Hayes; C C Johnson; J S Mandel; A Oberman; B O'Brien; M M Oken; S Rafla; D Reding; W Rutt; J L Weissfeld; L Yokochi; J K Gohagan Journal: Control Clin Trials Date: 2000-12
Authors: Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Claudine Isaacs; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Ann W Hsing; Grant Izmirlian; Paul F Pinsky; Barnett S Kramer; Anthony B Miller; John K Gohagan; Philip C Prorok Journal: J Natl Cancer Inst Date: 2012-01-06 Impact factor: 13.506
Authors: R Brunner; J Dunbar-Jacob; M S Leboff; I Granek; D Bowen; L G Snetselaar; S A Shumaker; J Ockene; M Rosal; J Wactawski-Wende; J Cauley; B Cochrane; L Tinker; R Jackson; C Y Wang; L Wu Journal: Behav Med Date: 2009 Impact factor: 3.104
Authors: Saundra S Buys; Edward Partridge; Amanda Black; Christine C Johnson; Lois Lamerato; Claudine Isaacs; Douglas J Reding; Robert T Greenlee; Lance A Yokochi; Bruce Kessel; E David Crawford; Timothy R Church; Gerald L Andriole; Joel L Weissfeld; Mona N Fouad; David Chia; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Patricia Hartge; Paul F Pinsky; Claire S Zhu; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; Jian-Lun Xu; Philip C Prorok; John K Gohagan; Christine D Berg Journal: JAMA Date: 2011-06-08 Impact factor: 157.335
Authors: Matti Hakama; Sue M Moss; Ulf-Hakan Stenman; Monique J Roobol; Marco Zappa; Sigrid Carlsson; Marco Randazzo; Vera Nelen; Jonas Hugosson Journal: J Med Screen Date: 2016-08-09 Impact factor: 2.136
Authors: S Fischer; S Sun; L E Howard; D M Moreira; R Castro-Santamaria; G L Andriole; A C Vidal; S J Freedland Journal: Prostate Cancer Prostatic Dis Date: 2016-03-01 Impact factor: 5.554